Belite Bio, Inc. ADR (BLTE) has released an update.
Belite Bio, Inc. has reported its third-quarter 2024 financial results, highlighting significant progress in its clinical trials for Tinlarebant, a promising treatment for Stargardt disease and geographic atrophy. The company has dosed its first patient in the Phase 2/3 DRAGON II trial and continues the Phase 3 PHOENIX trial with strong enrollment numbers. Belite also announced the appointment of Dr. Hendrik P.N. Scholl as Chief Medical Officer, boosting confidence in Tinlarebant’s potential.
For further insights into BLTE stock, check out TipRanks’ Stock Analysis page.
